International journal of clinical pharmacology and therapeutics最新文献_第3页

Exacerbations, mortality risk, and pharmacotherapy in COPD: Effect of 17 different drug combinations in a cohort of 495 patients. COPD的加重、死亡风险和药物治疗：495例患者中17种不同药物组合的效果

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-30 DOI: 10.5414/CP204727

Guoxin Wu, Ziyun Guan, Quankun Lv, Yi Ye, Jiacheng He, Jianwen Luo, Yanglin Cai, Zhixin Wu

{"title":"Exacerbations, mortality risk, and pharmacotherapy in COPD: Effect of 17 different drug combinations in a cohort of 495 patients.","authors":"Guoxin Wu, Ziyun Guan, Quankun Lv, Yi Ye, Jiacheng He, Jianwen Luo, Yanglin Cai, Zhixin Wu","doi":"10.5414/CP204727","DOIUrl":"https://doi.org/10.5414/CP204727","url":null,"abstract":"Objective: To assess the association between the severity of recent exacerbations and 90-day mortality risk in chronic obstructive pulmonary disease patients (COPD) with acute symptoms, focusing on the impact of the treatment regimen and involving 17 different drug combinations.Materials and methods: A longitudinal, retrospective analysis was carried out in 495 hospitalized COPD patients aged 40 - 75 years. Patients' clinical characteristics were recorded and the effects of drug regimens, administered pre and post hospitalization, comprising various combinations of long-acting muscarinic antagonists (LAMA), long-acting beta agonists (LABA), inhaled corticosteroids (ICS), and antibiotics, were compared. A statistical analysis of the primary outcome, 90-day mortality was used to identify patient attributes best predicting mortality.Results: At discharge, 65% of patients were receiving a 3-drug combination, 33% a 2-drug regimen, and 9% a single-drug therapy. Patients discharged on a 3-drug combination treatment had the lowest 90-day mortality rate (4%) compared to 22% for those treated with single-drug regimens. Multivariate analysis revealed that the risk of death on single-drug therapy was more than 5-fold greater (odds ratio 5.08) than in the case of patients discharged on a multi-drug combination regimen.Conclusion: Patients treated and discharged from hospital on a multi-drug regimen following recent COPD exacerbations had significantly better 90-day survival than patients discharged on monotherapy. The severity of exacerbations and nature of the pharmacotherapy were the main predictors of mortality and were indicative for the importance of disease assessment and multi-drug treatment strategies.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

H1 antihistamine-induced adverse events and time to onset: A retrospective analysis using the Japanese Adverse Drug Event Report Database. H1抗组胺诱导的不良事件和发病时间：使用日本不良药物事件报告数据库的回顾性分析。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-22 DOI: 10.5414/CP204707

Mikako Takatsuka, Masayuki Hashiguchi, Tsuyoshi Shiga

{"title":"H1 antihistamine-induced adverse events and time to onset: A retrospective analysis using the Japanese Adverse Drug Event Report Database.","authors":"Mikako Takatsuka, Masayuki Hashiguchi, Tsuyoshi Shiga","doi":"10.5414/CP204707","DOIUrl":"https://doi.org/10.5414/CP204707","url":null,"abstract":"Background: H1 antihistamines have not been systematically evaluated for adverse events (AEs) in real-world settings despite their widespread use in Japan. We investigated the characteristics of AEs caused by H1 antihistamines using the Japanese Adverse Drug Event Report (JADER) database.Materials and methods: We extracted 14 common AEs (including similar AEs) with a high frequency from the JADER database (April 2004 ‒ September 2023) for patients taking H1 antihistamines as \"suspected drugs\". Adjusted reporting odds ratios (aRORs) for sex and age were calculated to identify possible H1 antihistamines. A time-event analysis was performed using a Weibull distribution.Results: Among the 32,592 case reports where H1 antihistamines were identified as \"suspected drugs\", a total of 9,549 case reports involving 2,881 patients were extracted for the common 14 AEs associated with 6 first-generation and 16 second-generation drugs. Among these patients, 53.6% were female, and patients aged 50 - 79 years had a high incidence (45.7%). The highest aROR was for alopecia (56.6), followed by angioedema (3.2), hepatotoxicity (2.6), loss of consciousness (2.4), and Stevens-Johnson syndrome (2.1). Anaphylaxis, Stevens-Johnson syndrome, drug/toxic eruption, angioedema, and convulsions/epilepsy occurred within 1 week of H1 antihistamine use. Hepatotoxicity, loss of consciousness, convulsion/epilepsy, pneumonia and aplastic anemia occurred over time throughout H1 antihistamine treatment. The shape parameter β values of most AEs were < 1.0.Conclusion: This study revealed that most severe AEs, such as anaphylaxis and toxic cutaneous diseases, caused by H1 antihistamines occurred within 1 week of treatment. Hepatotoxicity, alopecia, interstitial pneumonia, and aplastic anemia occurred throughout the treatment period.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe autoimmune hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency as a complication of nivolumab treatment: A case report. 作为纳武单抗治疗并发症的严重自身免疫性溶血性贫血与葡萄糖-6-磷酸脱氢酶缺乏相关：1例报告

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-22 DOI: 10.5414/CP204756

Roberto Lozano, María-Esther Franco, Carina Bona

引用次数: 0

Matrix-induced autologous chondrocyte implants in osteoarthritis: Procedures to prevent adverse events based on data-mining of the FAERS database. 骨关节炎基质诱导的自体软骨细胞植入物：基于FAERS数据库数据挖掘的预防不良事件的程序。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-22 DOI: 10.5414/CP204730

Zhi Chen, Fanglu Xu, Bingqian Chen, Jie Ma, Chaoshen Wu, Hongtao Zhang, Da Qian, Guoxin Huang

引用次数: 0

Evidence for a loss of analgesia when hydromorphone is administered in combination with hange-shashin-to: Enterohepatic circulation and β-glucuronidase inhibition. 氢吗啡酮与黄-沙辛-托联合使用镇痛丧失的证据：肠肝循环和β-葡萄糖醛酸酶抑制。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204702

Masakazu Ozaki, Hiroshi Yamagata, Hiroto Matsui, Naoto Okada, Mishiya Matsumoto, Hiroaki Nagano, Takashi Kitahara

引用次数: 0

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204724

Mingtao Chen, Lin Zhou, Huijuan Yang, Mengmeng Wang

引用次数: 0

Cardiovascular safety profile of JAK inhibitors and ethnic factors in Asians: A signal detection study using the Global ICSR (WHO-UMC VigBase) database. 亚洲人JAK抑制剂和种族因素的心血管安全性概况：使用全球ICSR （WHO-UMC VigBase）数据库的信号检测研究

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204580

Woongshik Nam, Ji-Hwan Bae, Jeongin Oh, Ju-Young Shin, Hoon Kim

引用次数: 0

Severe genital cutaneous toxicity with sunitinib. 苏尼替尼严重的生殖器皮肤毒性。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204697

María Rodríguez Jorge, Loreto Domínguez Senín, Stephanie Saide Cobelas Cartagena, María Sánchez Esperilla, Juan Bayo Calero

{"title":"Severe genital cutaneous toxicity with sunitinib.","authors":"María Rodríguez Jorge, Loreto Domínguez Senín, Stephanie Saide Cobelas Cartagena, María Sánchez Esperilla, Juan Bayo Calero","doi":"10.5414/CP204697","DOIUrl":"10.5414/CP204697","url":null,"abstract":"Introduction: Sunitinib is an oral drug approved for the treatment of metastatic renal cell carcinoma. Serious cutaneous adverse reactions to sunitinib are rare, and when they occur, discontinuation of the treatment may be needed.Case report: A 70-year-old male patient was diagnosed with stage IV clear cell renal carcinoma and received treatment with sunitinib. After a second cycle with a 25% dose reduction, the patient was admitted with a diagnosis of grade 3 genital erythema. After ruling out other common causes, sunitinib was considered the cause of genital erythema and was stopped. Treatment with corticosteroids, topical applications, and morphine was started, with resolution after 18 days of evolution.Discussion: There are only a few published reports that describe erythema and scaling of the genital skin. As in those few cases, for our patient, the first clinical signs appeared on day 28 of sunitinib treatment, and the lesions disappeared after 2 weeks without the use of the drug. Erythema and scaling reappeared when the drug was reintroduced, with greater severity than what was described in some of the other cases, which even included cases for which the lesions did not reappear.Conclusion: Rare instances of severe and limiting skin toxicity may necessitate treatment suspension and compromise survival, as observed in our case. It is crucial to recognize these skin toxicities and understand their appropriate management strategies to initiate treatment as early as possible, thereby avoiding hospitalizations and enabling the resumption of sunitinib therapy.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"164-168"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease. GLP-1激动剂dulaglutide的肾保护作用，涉及调节2型糖尿病和糖尿病肾病患者的上皮-间质转化。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204632

Daoli Jiang, Fandong Meng, Xiaohua Chou, Jiaxin Shen, Miaoyan Liu

{"title":"Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.","authors":"Daoli Jiang, Fandong Meng, Xiaohua Chou, Jiaxin Shen, Miaoyan Liu","doi":"10.5414/CP204632","DOIUrl":"10.5414/CP204632","url":null,"abstract":"Aims: To assess the renoprotective effects of dulaglutide and identify mechanisms of action in patients with type 2 diabetes and diabetic kidney disease (DKD).Materials and methods: Outpatients/ambulant patients at the Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University between October 2021 and July 2023, with type 2 diabetes and DKD, a urinary albumin-to-creatinine ratio (UACR) ≥ 3 mg/mmol and who were receiving hypoglycemic agents were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70). Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65). Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment. Adverse events (estimates of tolerability and safety) were recorded during treatment and a follow-up period of 12 months.Results: UACR changes in the intervention group compared to the control group were significantly lower (p < 0.01 at 6 months and p < 0.05 at 12 months). The frequency of gastrointestinal adverse events in the two groups were not significantly different, and there were no significant increases in the number of hypoglycemic events. Dulaglutide significantly increased the epithelial marker E-cadherin and inhibited the mesenchymal marker periostin.Conclusion: It is concluded that dulaglutide causes significant reductions in urinary albumin and modulates EMT-related proteins thereby ameliorating the decline in kidney function in patients with type 2 diabetes and DKD.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"141-153"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis. 双膦酸盐联合阿仑膦酸钠可增加骨质疏松症患者的骨密度，调节IL-6、TNF-α和IGF-1。

IF 0.9 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2025-04-01 DOI: 10.5414/CP204706

Xuechun Gu, Liyuan Zhang, Xiangyi Chen, Lingyan Kong

{"title":"Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis.","authors":"Xuechun Gu, Liyuan Zhang, Xiangyi Chen, Lingyan Kong","doi":"10.5414/CP204706","DOIUrl":"10.5414/CP204706","url":null,"abstract":"Objective: To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor I (IGF-I) in patients with osteoporosis.Materials and methods: A total of 94 patients recruited from osteoporosis patients hospitalized in the period October 2021 to December 2022 were assigned to either a control group or an observation group using a random number table. The control group was treated with alendronate sodium alone, whereas the observation group received zoledronic acid injection in combination with alendronate sodium administered orally.Results: Pre-treatment values for BMD, serum levels of IL-6, TNF-α, and IGF-I did not differ between the two groups (p > 0.05). However, post-treatment BMD measured at the femoral neck, in lumbar vertebrae, and Ward's triangle were increased, as was serum IGF-I level (p < 0.05). In contrast, in comparison with the control group, reductions were observed in serum IL-6 and TNF-α (p < 0.05). The incidence of adverse reactions such as nausea and vomiting, diarrhea, musculoskeletal pain, and hypocalcemia was significantly lower in the observation group (p < 0.05).Conclusion: Zoledronic acid injection in combination with alendronate sodium increases the expression of IL-6, TNF-α, and IGF-I, suppresses bone resorption and promotes bone recovery in patients with osteoporosis.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"154-159"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0